Reid Hoffman

Reid Hoffman (Director) sold entire 1.20M share stake in AUR for $8.7M at $7.27; complete exit from position.

Reid Hoffman filed three separate sales totaling 1,202,354 shares for $8,746,043.22 on 2026-05-28, reducing his holdings from 1.20M shares to zero—a complete exit. The blended average sale price of $7.27 represents a sale during a period of significant upward momentum: the stock is up 42.8% over 30 days and 51.1% over 90 days from transaction date. However, his prior trades at Aurora Innovation show a strong pattern: 5 of 5 prior sells at this ticker were well-timed, with post-sale declines of -9.3% to -12.8% at the 90-day mark. The company's fundamental picture is relevant—it reported $1.0M in quarterly revenue against a $-223.0M net loss, reflecting significant unprofitability. A director's complete liquidation of a $8.7M position, particularly given the insider's demonstrated ability to time exits at this ticker and the company's loss-making financial position, warrants investor attention as a material signal of conviction shift.

Director Reid Hoffman sold 5,846,133 shares (5.85M) for $45,542,438.97, reducing stake by 99.0% to 60,118 shares.

Reid Hoffman (Director) executed 6 separate sales totaling 5,846,133 shares for $45,542,438.97 between May 15–18, 2026, at blended average price $7.79. This represents a -99.0% reduction in his pre-transaction holdings of 5,906,251 shares, leaving only 60,118 shares post-transaction. The sales occurred at prices well above the current price of $7.07 and within the 52-week range of $3.60–$8.56. Notably, his prior 5 sales at AUR (dated November 2024) all posted positive 90-day returns (+30.6% to +38.2%), with a 0.00% well-timed rate at the 90-day mark—meaning the stock continued to appreciate after each prior sale. The company reported Revenue of $1,000,000.00 (latest quarter) and Net income of $-223,000,000.00, indicating ongoing unprofitability that may inform the scale and timing of this near-total liquidation.

10% owner Reprogrammed Interchange LLC sold 37,533 shares (37.5K) across 4 sales totaling $1,133,103.32 at VOR, reducing stake to 1,166,909 shares.

Reprogrammed Interchange LLC, a 10% owner of Vor Biopharma, executed 4 separate sales totaling 37,533 shares for $1,133,103.32 between 2025-10-17 and 2025-10-21 at prices ranging from $30.05 to $31.00. The company is unprofitable with net income of $-1,573,669,000.00 over its most recent full fiscal year. Stock has declined 33.6% over the past 90 days and is trading 48.0% below its 52-week high of $53.40 at the current price of $27.77, well below the blended sale price of $30.19. The insider retains 1,166,909 shares post-transaction, representing a 3.1% reduction from the 1,204,442 shares held pre-transaction, maintaining substantial ownership concentration.

10% owner Reprogrammed Interchange LLC sold 73,676 shares (73.7K) for $2.3M at blended avg $31.88 as VOR stock down 45.7% from 52-week high.

Reprogrammed Interchange LLC, a 10% shareholder, executed four separate sales totaling 73,676 shares for $2,348,744.16 over two trading days (October 15–16, 2025), reducing holdings by 5.8% to 1,204,442 shares. The sales occurred at prices ranging from $30.45 to $32.77, with a blended average of $31.88, while the current stock price is $29.00—indicating the insider sold above recent market levels. The timing is notable: VOR's stock has fallen 45.7% from its 52-week high of $53.40 and is down 34.4% over the 90-day period, yet the company reported a net loss of $1,573,669,000 over its most recent full fiscal year. The insider's recent selling pattern at this ticker shows five prior transactions within the last few days (October 13–17), suggesting heightened liquidation activity. This concentrated divestiture by a significant shareholder warrants scrutiny given the company's unprofitability and the sharp equity decline, though the absence of scheduled trading plan disclosures prevents determination of whether sales were discretionary or automated.

10% owner Reprogrammed Interchange LLC sold 96,657 shares across 4 sales totaling $3,003,705.80 at VOR; stock down 43.4% from 52-week high.

Reprogrammed Interchange LLC, a 10% owner, executed 4 separate sales totaling 96,657 shares for $3,003,705.80 between October 10-14, 2025, at a blended average price of $31.08. The stock has fallen 43.4% from its 52-week high of $53.40 and currently trades at $30.22, just below the transaction prices—indicating the sales occurred near recent support levels. The company is unprofitable with a net loss of $1,573,669,000.00 and a market cap of $3,828,363,614.42. While the insider still holds 1,278,118 shares post-transaction (retaining a substantial position at 1.28M shares), the reduction of 96,657 shares represents a 7.0% decrease in holdings. The cross-ticker track record shows 20 prior sells with an average 30-day return of +1741.8%, though the outcome is not predictive of this specific transaction in an unprofitable biotech company experiencing significant recent price erosion.

10% owner Reprogrammed Interchange LLC sold 124,146 shares for $4.1M across 4 transactions on Oct 8–9 at blended avg $33.16

Reprogrammed Interchange LLC, a 10% shareholder in Vor Biopharma, executed 4 separate sales totaling 124,146 shares for $4,116,368.53 on October 8–9, 2025, reducing holdings by -8.3% to 1,374,775 shares. The blended average sale price of $33.16 is 6.2% above the current price of $31.23, though the stock has declined -41.5% from its 52-week high and -13.2% over 30 days. Vor remains unprofitable with a net income of $-1,573,669,000.00 over its most recent full fiscal year. The insider's cross-ticker track record shows 20 prior sells with an average 30-day return of +1622.0%, but at the VOR ticker specifically, 5 prior sells have outcomes not yet measurable. This large stake reduction by a major shareholder during a period of significant stock weakness and negative fundamentals merits investor attention to understand the motivation behind the sale.

10% owner Reprogrammed Interchange sells 98,387 shares ($3.6M) at $36.12 avg; stock down -37.4% from 52-week high, company unprofitable.

Reprogrammed Interchange LLC, a 10% owner of Vor Biopharma, executed 4 separate sales on October 6–7, 2025, totaling 98,387 shares (1.50M shares remain post-transaction). The sales occurred at blended average price of $36.12, representing 6.2% reduction in holdings. Notably, the current stock price is $33.40, down -37.4% from the 52-week high of $53.40 and declining -15.7% over the prior 30 days. The underlying company posted net income of $-1,573,669,000.00 and a market cap of $4,231,215,907.40, confirming it was unprofitable over the most recent full fiscal year. The timing of this substantial sale coincides with significant downward price pressure and sustained losses, though the multi-transaction nature and recent execution date preclude measurement of 90-day outcomes at this filing.

10% owner Reprogrammed Interchange LLC sells 41,752 shares over 3 days (Oct 1–3) for $1,646,237.32; 5 prior VOR sells within 3 weeks; stock down 6.4% (30d)

Reprogrammed Interchange LLC, a 10% owner, executed 8 separate sales totaling 41,752 shares for $1,646,237.32 between October 1–3, 2025, at blended average price $39.43. This follows 5 prior sales at VOR within the preceding 3 weeks (September 9–15), indicating concentrated selling activity by a major shareholder over a narrow window. Post-transaction holdings remain substantial at 1,597,308 shares (1.60M shares), representing a net reduction of 2.5% vs. pre-transaction holdings. The timing occurs against a backdrop of stock weakness: the current price ($37.46) is -6.4% over the 30-day period and -29.8% from the 52-week high. The company's most recent full fiscal year showed net income of $-1,573,669,000.00 ($-1.6B), indicating material unprofitability. An investor should monitor whether this pattern of sustained sales by a major insider reflects broader concerns about the company's trajectory.

10% owner Reprogrammed Interchange sells 984,805 shares (984.8K) across 3 tranches at $1.73–$1.83 for $1.7M as stock recovers +676% in 90 days from lows.

Reprogrammed Interchange LLC executed 3 separate sales totaling 984,805 shares for $1,703,970.99 at a blended average price of $1.73 (ranging $1.64–$1.83 across September 11–15). This represents a -2.9% reduction of the 10% owner's position from 34.21M to 33.23M shares. The transaction timing is notable: the stock is currently priced at $32.00 but has surged +676.0% over 90 days from recent lows while sitting -40.1% below its 52-week high of $53.40. The company remains unprofitable with a net loss of $-1,573,669,000.00 over its most recent fiscal year. No prior sell outcomes at this ticker are yet measurable, and the insider's cross-ticker sales history shows a 0.00% win rate on 90-day returns, suggesting inconsistent timing discipline on the sell side.

10% owner Reprogrammed Interchange LLC sold 1,263,647 shares of VOR at $1.95–$2.00 (Sept 8–10) for $2,457,975.15; stock now $36, up 769.6% in 90 days.

Reprogrammed Interchange LLC, a 10% shareholder, conducted 3 separate sales totaling 1,263,647 shares for $2,457,975.15 over three trading days (September 8–10, 2025), reducing holdings by 3.6% from 35,476,939 to 34,213,292 shares. The blended average sale price was $1.95, but VOR has since risen to $36.00 (769.6% gain in 90 days), meaning the insider sold well below current levels. The company remains unprofitable with a net loss of $1,573,669,000.00 and a market cap of $4,560,591,996.00, suggesting that the recent stock surge reflects valuation volatility rather than earnings-driven performance. The insider's cross-ticker track record shows a 0.00% 90-day win rate on prior sells, providing no confidence in sell-timing accuracy, though same-ticker timing outcomes remain unmeasurable at this early stage.